The DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.
Maintenance of antidepressant and antisuicidal effects by D-cycloserine among patients with treatment-resistant depression who responded to low-dose ketamine infusion: a double-blind randomized placebo–control study
Open accessAbstract
Increasing evidence supports a rapid antidepressant and antisuicidal effect of a single subanesthetic dose of ketamine infusion for treatment-resistant depression (TRD). Maintaining the initial clinical response after ketamine infusion in TRD is a crucial next-step challenge. D-cycloserine (DCS), a partial agonist of the glycine co-agonist of the N-methyl-D-aspartate (NMDA) glutamate receptor, is potentially effective as a depression augmentation treatment. However, whether DCS maintains the antidepressant and antisuicidal effects of ketamine infusion remains unknown. In all, 32 patients with TRD (17 with major depression and 15 with bipolar depression) who responded to ketamine infusion with an average 17-item Hamilton Depression Rating Scale (HAMD) score of 9.47 ± 4.11 at baseline were randomly divided to 6-week DCS treatment (250 mg for 2 days, 500 mg for 2 days, 750 mg for 3 days, and 1000 mg for 5 weeks) and placebo groups. Depression symptoms were rated at timepoints of dose titration and weekly. During the 6-week treatment, the total scores of HAMD did not differ between the DCS and placebo groups. The results remained consistent when stratified by disorder. A mixed model analysis indicated that the DCS group exhibited lower scores of HAMD item 3 (suicide) compared with the placebo group throughout the follow-up period (p = 0.01). A superior maintenance of the antisuicidal effect of ketamine was observed in the DCS group than in the placebo group. DCS may be therapeutically beneficial for patients with TRD who responded to ketamine infusion but have a residual suicidal risk.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“one study of individuals with either MDD or bipolar depression (n = 32) found that although it was unable to differentiate from placebo in maintaining an antidepressant effect”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [175]
In the citing paper
“it was superior in maintaining ketamine's antisuicidal effects [175]”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [175]
In the citing paper
“Combining ketamine with other NMDA allosteric modulators such as D-cycloserine (DCS) or riluzole may also prolong anti-suicidal effects for over 6 weeks in TRD patients [97].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [97]
In the citing paper
“Esketamine’s putative mechanism of action likely involves a similar, transient surge in glutamatergic transmission, accompanied by increased synaptogenesis and an influx in neurotrophic factor activity [46,77,97].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [97]
In the citing paper
“In all reports, initial efficacy was either transient or inconsistent in larger studies [97,103,144,145,146].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [97]
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
(1998) · The Journal of Clinical Psychiatry · Cited by 19,139
(1998) · PubMed · Cited by 10,216
Murrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Green, C. E., Perez, A. M., Iqbal, S., Pillemer, S., Foulkes, A., Shah, A., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13030392 · Cited by 1,205
Treatment-resistant depression: therapeutic trends, challenges, and future directions
Al-harbi (2012) · Patient Preference and Adherence · doi:10.2147/ppa.s29716 · Cited by 796
Murrough, J. W., Perez, A. M., Pillemer, S., Stern, J., Parides, M. K., aan het Rot, M., Collins, K. A., Mathew, S. J., Charney, D. S., & Iosifescu, D. V. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.06.022 · Cited by 786
Wilkinson, S. T., Ballard, E. D., Bloch, M. H., Mathew, S. J., Murrough, J. W., Feder, A., Sos, P., Wang, G., Zarate, C. A., & Sanacora, G. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17040472 · Cited by 696
Danysz, W., & Parsons, C. G. (1998) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01382-6 · Cited by 649
Effects of D-Cycloserine on Extinction: Translation From Preclinical to Clinical Work
Davis, M., Ressler, K., Rothbaum, B. O., & Richardson, R. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.03.084 · Cited by 498
Phillips, J. L., Norris, S., Talbot, J., Birmingham, M., Hatchard, T., Ortiz, A., Owoeye, O., Batten, L. A., & Blier, P. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18070834 · Cited by 418
Cited by
Jha, M. K., & Mathew, S. J. (2023) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230025 · Cited by 130
Ketamine in neuropsychiatric disorders: an update
Johnston, J. N., Kadriu, B., Kraus, C., Henter, I. D., & Zarate, C. A. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-023-01632-1 · Cited by 108
“…clinical response after ketamine administration; one study of individuals with either MDD or bipolar depression ( n = 32) found that although it was unable to differentiate from placebo in maintaining an antidepressant effect, it was superior in maintaining ketamine ’ s antisuicidal effects [175].”
BackgroundKantrowitz, J. T., Dong, Z., Milak, M. S., Rashid, R., Kegeles, L. S., Javitt, D. C., Lieberman, J. A., & John Mann, J. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01541-1 · Cited by 100
Li, J., Wang, Z., Wang, A., & Wang, Z. (2022) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13604 · Cited by 102
Cole, J., Sohn, M. N., Harris, A. D., Bray, S. L., Patten, S. B., & McGirr, A. (2022) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2022.3255 · Cited by 93
Metadata
- Authors
- Chen, M.-H., Cheng, C.-M., Gueorguieva, R., Lin, W.-C., Li, C.-T., Hong, C.-J., Tu, P.-C., Bai, Y.-M., Tsai, S.-J., Krystal, J. H., & Su, T.-P.
- Affiliations
- Taipei Veterans General Hospital (TW)
- Yale University (US)
- Yale New Haven Hospital (US)
- Corresponding author
- Krystal, John H.
- Su, Tung-Ping
- ORCID
- Venue
- Neuropsychopharmacology
- Published
- 2019-08-17
- Volume
- 44
- Issue
- 12
- Pages
- 2112-2118
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- PMC
- PMC6898334
- OpenAlex
- W2969121736
- Cited by
- 84
- References
- 40
- Citations by year
- 2026: 12 · 2025: 11 · 2024: 8 · 2023: 17 · 2022: 14 · 2021: 14 · 2020: 7
- FWCI
- 5.42
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Veterans Affairs (UL1RR024139, P50AA12870)
- Taipei Veterans General Hospital
- National Institutes of Health (UL1TR001863)
- National Center for PTSD, U.S. Department of Veterans Affairs
- National Institute on Alcohol Abuse and Alcoholism (P50AA012870)
- National Center for Research Resources (M01RR000125, UL1RR024139)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- D-cycloserine, ketamine infusion, treatment-resistant depression, antidepressant maintenance, antisuicidal effects, NMDA receptor partial agonist, glycine co-agonist, bipolar depression, major depressive disorder, suicide risk
- MeSH terms
- Suicide Prevention, Adult, Antidepressive Agents, Bipolar Disorder, Cycloserine, Major Depressive Disorder, Double-Blind Method, Female, Humans, Ketamine, Male, Middle Aged, Treatment Outcome, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Maintenance of antidepressant and antisuicidal effects by D-cycloserine among patients with treatment-resistant depression who responded to low-dose ketamine infusion: a double-blind randomized placebo–control study. https://app.cochat.ai/papers/10.1038/s41386-019-0480-y
- The paper
- Chen, M.-H., Cheng, C.-M., Gueorguieva, R., Lin, W.-C., Li, C.-T., Hong, C.-J., Tu, P.-C., Bai, Y.-M., Tsai, S.-J., Krystal, J. H., & Su, T.-P. (2019). Maintenance of antidepressant and antisuicidal effects by D-cycloserine among patients with treatment-resistant depression who responded to low-dose ketamine infusion: a double-blind randomized placebo–control study. Neuropsychopharmacology. https://doi.org/10.1038/s41386-019-0480-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.